The impact of biotin interference on laboratory testing and patient diagnosis in clinical practice-Reference-Cited by-同舟云学术

The impact of biotin interference on laboratory testing and patient diagnosis in clinical practice

Published:2019-12 Issue:1 Volume:4 Page:
ISSN:2053-0846
Container-title:International Journal of Pharmacokinetics
language:en
Short-container-title:International journal of Pharmacokinetics

Author:

Giovanella Luca¹

Affiliation:

1. Clinic for Nuclear Medicine & Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland/Ente Ospedaliero Cantonale, Via Ospedale 6, 6500 Bellinzona, Switzerland

Publisher

Future Science Ltd

Link

https://www.future-science.com/doi/pdf/10.4155/ipk-2019-0001

Reference20 articles.

1. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis

2. US Food and Drug Administration. The FDA warns that biotin may interfere with lab tests: FDA safety communication (28 November 2017). www.fda.gov/medicaldevices/safety/alertsandnotices/ucm586505.htm (27 November 2018)

3. Biotin interference on immunoassay methods: sporadic cases or hidden epidemic?

4. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences

5. Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective quantification of the 22-kDa isoform of human growth hormone 1 in serum and plasma by immunocapture and LC–MS/MS;Analytical and Bioanalytical Chemistry;2022-07-15

2. Serum Biotin Levels in General Korean Population;Laboratory Medicine Online;2022-07-01